LARIMAR THERAPEUTICS, INC. Payments to Acquire Debt Securities, Available-for-sale
LARIMAR THERAPEUTICS, INC. (LRMR) reported Payments to Acquire Debt Securities, Available-for-sale of $63.28 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-04
- LARIMAR THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- LARIMAR THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $3.46M, a 84.74% decline year-over-year.
- LARIMAR THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-06-30 was $27.64M, a 66.18% decline year-over-year.
- LARIMAR THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-03-31 was $52.50M, a 38.13% decline year-over-year.
- LARIMAR THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $83.60M, a 63.31% decline from fiscal 2024.
- LARIMAR THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $227.87M, a 125.10% increase from fiscal 2023.
- LARIMAR THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $101.23M, a 24.23% decline from fiscal 2022.
- LARIMAR THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $133.61M, a 1519.91% increase from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $63.28M 10-Q · filed 2026-08-04 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $3.46M derived: sum of 2 quarters · filed 2026-03-19 | $31.10M derived: sum of 3 quarters · filed 2026-08-04 | $83.60M 10-K · filed 2026-03-19 |
| 2025-09-30 | $3.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $31.10M derived: sum of 2 quarters · filed 2026-08-04 | $83.60M 10-Q · filed 2025-11-05 | $122.22M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $27.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $80.14M 10-Q · filed 2026-08-04 | $118.77M derived: sum of 3 quarters · filed 2026-08-04 | $141.43M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $52.50M 10-Q · filed 2026-05-14 | $91.13M derived: sum of 2 quarters · filed 2026-05-14 | $113.79M derived: sum of 3 quarters · filed 2026-05-14 | $195.51M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $38.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $61.29M derived: sum of 2 quarters · filed 2026-03-19 | $143.01M derived: sum of 3 quarters · filed 2026-03-19 | $227.87M 10-K · filed 2026-03-19 |
| 2024-09-30 | $22.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $104.38M derived: sum of 2 quarters · filed 2025-11-05 | $189.25M 10-Q · filed 2025-11-05 | $224.21M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $81.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $166.58M 10-Q · filed 2025-08-14 | $201.55M derived: sum of 3 quarters · filed 2025-08-14 | $257.97M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $84.86M 10-Q · filed 2025-04-30 | $119.83M derived: sum of 2 quarters · filed 2025-04-30 | $176.25M derived: sum of 3 quarters · filed 2025-04-30 | |
| 2023-12-31 | $34.97M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $91.39M derived: sum of 2 quarters · filed 2025-03-24 | $101.23M 10-K · filed 2025-03-24 | |
| 2023-09-30 | $56.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $66.27M 10-Q · filed 2024-10-30 | ||
| 2023-06-30 | $9.85M 10-Q · filed 2024-08-08 | |||
| 2022-12-31 | $71.98M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $98.37M derived: sum of 2 quarters · filed 2024-03-14 | $133.61M 10-K · filed 2024-03-14 | |
| 2022-09-30 | $26.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $61.63M 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | $35.24M 10-Q · filed 2023-08-10 | |||
| 2021-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $6.50M derived: sum of 2 quarters · filed 2023-03-14 | $6.50M derived: sum of 3 quarters · filed 2023-03-14 | $8.25M 10-K · filed 2023-03-14 |
| 2021-09-30 | $6.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $6.50M derived: sum of 2 quarters · filed 2022-11-10 | $8.25M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $1.75M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $1.75M 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $24.49M 10-K · filed 2022-03-25 | |||
| 2020-03-31 | $2.34M 10-Q · filed 2020-05-07 | $14.16M derived: sum of 2 quarters · filed 2020-05-07 | $24.06M derived: sum of 3 quarters · filed 2020-05-07 | $51.73M derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-12-31 | $11.83M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $21.72M derived: sum of 2 quarters · filed 2020-03-05 | $49.40M derived: sum of 3 quarters · filed 2020-03-05 | $82.86M 10-K · filed 2020-03-05 |
| 2019-09-30 | $9.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $37.57M derived: sum of 2 quarters · filed 2019-11-06 | $71.03M 10-Q · filed 2019-11-06 | $82.21M derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-06-30 | $27.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $61.14M 10-Q · filed 2019-08-08 | $72.31M derived: sum of 3 quarters · filed 2020-05-07 | $142.42M derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-03-31 | $33.47M 10-Q · filed 2020-05-07 | $44.64M derived: sum of 2 quarters · filed 2020-05-07 | $114.74M derived: sum of 3 quarters · filed 2020-05-07 | $137.73M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $11.17M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $81.28M derived: sum of 2 quarters · filed 2020-03-05 | $104.27M derived: sum of 3 quarters · filed 2020-03-05 | $117.15M 10-K · filed 2020-03-05 |
| 2018-09-30 | $70.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $93.10M derived: sum of 2 quarters · filed 2019-11-06 | $105.98M 10-Q · filed 2019-11-06 | $131.31M derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-06-30 | $22.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $35.87M 10-Q · filed 2019-08-08 | $61.20M derived: sum of 3 quarters · filed 2020-03-05 | $93.08M derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-03-31 | $12.88M 10-Q · filed 2019-05-09 | $38.21M derived: sum of 2 quarters · filed 2020-03-05 | $70.09M derived: sum of 3 quarters · filed 2020-03-05 | $94.60M derived: sum of 4 quarters · filed 2020-03-05 |
| 2017-12-31 | $25.33M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $57.21M derived: sum of 2 quarters · filed 2020-03-05 | $81.72M derived: sum of 3 quarters · filed 2020-03-05 | $114.51M 10-K · filed 2020-03-05 |
| 2017-09-30 | $31.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $56.39M derived: sum of 2 quarters · filed 2018-11-09 | $89.18M 10-Q · filed 2018-11-09 | $119.53M derived: sum of 4 quarters · filed 2019-03-14 |
| 2017-06-30 | $24.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $57.30M 10-Q · filed 2018-08-09 | $87.66M derived: sum of 3 quarters · filed 2019-03-14 | $123.92M derived: sum of 4 quarters · filed 2019-03-14 |
| 2017-03-31 | $32.79M 10-Q · filed 2018-05-10 | $63.15M derived: sum of 2 quarters · filed 2019-03-14 | $99.41M derived: sum of 3 quarters · filed 2019-03-14 | $134.86M derived: sum of 4 quarters · filed 2019-03-14 |
| 2016-12-31 | $30.36M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $66.62M derived: sum of 2 quarters · filed 2019-03-14 | $102.07M derived: sum of 3 quarters · filed 2019-03-14 | $136.53M 10-K · filed 2019-03-14 |
| 2016-09-30 | $36.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $71.71M derived: sum of 2 quarters · filed 2017-11-07 | $106.17M 10-Q · filed 2017-11-07 | $146.89M derived: sum of 4 quarters · filed 2018-03-09 |
| 2016-06-30 | $35.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $69.91M 10-Q · filed 2017-08-09 | $110.63M derived: sum of 3 quarters · filed 2018-03-09 | $198.77M derived: sum of 4 quarters · filed 2018-03-09 |
| 2016-03-31 | $34.46M 10-Q · filed 2017-05-09 | $75.18M derived: sum of 2 quarters · filed 2018-03-09 | $163.32M derived: sum of 3 quarters · filed 2018-03-09 | $223.00M derived: sum of 4 quarters · filed 2018-03-09 |
| 2015-12-31 | $40.72M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $128.86M derived: sum of 2 quarters · filed 2018-03-09 | $188.54M derived: sum of 3 quarters · filed 2018-03-09 | $287.49M 10-K · filed 2018-03-09 |
| 2015-09-30 | $88.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $147.82M derived: sum of 2 quarters · filed 2016-11-09 | $246.77M 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $59.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $158.63M 10-Q · filed 2016-08-05 | ||
| 2015-03-31 | $98.95M 10-Q · filed 2016-05-10 | |||
| 2014-12-31 | $57.20M 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |